Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Celldex Therapeutics, Inc.

Biotech SG&A Expenses: Vertex vs. Celldex

__timestampCelldex Therapeutics, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 201420622000305409000
Thursday, January 1, 201533837000377080000
Friday, January 1, 201635979000432829000
Sunday, January 1, 201725003000496079000
Monday, January 1, 201819269000557616000
Tuesday, January 1, 201915426000658498000
Wednesday, January 1, 202014456000770456000
Friday, January 1, 202120488000840100000
Saturday, January 1, 202227195000944700000
Sunday, January 1, 2023309140001136600000
Monday, January 1, 20241464300000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Vertex Pharmaceuticals Incorporated and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Vertex Pharmaceuticals has consistently outpaced Celldex in SG&A spending, reflecting its larger scale and broader market reach. In 2023, Vertex's SG&A expenses were approximately 3.7 times higher than in 2014, showcasing a robust growth trajectory. Meanwhile, Celldex's expenses have fluctuated, peaking in 2016 and showing a resurgence in 2023. This divergence highlights the different strategic paths these companies have taken, with Vertex investing heavily in administrative capabilities to support its expanding operations. As the biotech industry continues to evolve, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.

Financial Strategies in Biotech: A Comparative Insight

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025